Treatment for adults up to 65 with newly diagnosed ALL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a treatment plan for adults aged 18 to 65 who have just been diagnosed with a type of acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome (Ph-negative). The goal is to see how well this therapy works and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have newly diagnosed ALL that is Ph-negative
- You must be between 18 and 65 years old
- You have not had any prior treatment for this leukemia, except for urgent procedures like leukapheresis or certain radiation
- You must be in good general health (ECOG score 0-2), or if your score is higher, it must be due to the ALL itself
- If you are a woman who could become pregnant, you must have a negative pregnancy test
- You cannot have heart disease, severe liver disease, severe lung problems, kidney failure not caused by ALL, or certain other conditions that would make treatment unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a standard chemotherapy regimen for people aged 18 to 50 with a type of leukemia called Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to see how well the treatment works for this age group.
This study tests adding new immunotherapy drugs and possibly a stem cell transplant to the first treatment for adults with acute lymphoblastic leukemia (ALL). The goal is to see if these approaches help people live longer without the cancer coming back.
This trial tests a combination of two targeted drugs (blinatumomab and asciminib) for people with a specific type of leukemia (Ph+ ALL). The goal is to see if the combination works better than either drug alone in controlling the leukemia.
This trial tests a treatment plan for children newly diagnosed with low-risk B-cell ALL. It aims to improve outcomes while reducing side effects.
This trial tests a treatment plan for children and teens newly diagnosed with B-cell acute lymphoblastic leukemia (ALL) that is intermediate or high risk. The goal is to find the best way to treat the cancer and improve outcomes.
This trial tests a new treatment plan for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It aims to see if the combination of drugs can effectively control the leukemia while keeping side effects manageable.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.